It's timefor the whole heart. Ventripoint (TSXV: VPT) has redesigned VMS to meet the demands of every market. Preparing to move beyond the Left and Right Ventricle to become the first platform to offer 3D volumes for all cardiac chambers, with accuracy equivalent to MRI.....all from the convenience of 2D Ultrasound.

For those interested in distribution opportunities, please use the Distributor contact form.

Cleveland Clinic says...

“The VMS™ will enable us to better image the hearts of patients at risk for pulmonary hypertension and is a wonderful alternative to MRI."

University of Chicago says...

“I expect that an assessment of RV volume and function using the VMS™ will become part of the routine clinical ultrasound evaluation for patients at risk for PAH. A simple way to detect and monitor PAH is gravely needed and this methodology will be extremely useful to quantify interventions (therapeutic and surgical) performed on the right ventricle,” stated Roberto M. Lang, MD, is an internationally renowned cardiologist and specialist in echocardiography and Past President of the American Society of Echocardiography.

Hospital for Sick Kids says...

“We found an excellent agreement between both techniques and, based on these findings, decided to introduce the method in our Echocardiography Laboratory. The first results of a clinical trial to evaluate feasibility, reproducibility and accuracy of the system are really impressive and demonstrate that the VMS is a robust clinical tool. I see a multitude of potential applications for the VMS that can significantly impact the care of patients with heart disease,” said Luc Mertens MD, Head, Echocardiography Cardiology.

Continuous Disclosure: VentriPoint Diagnostics Ltd. is a public Canadian company with its common shares traded on the TSX Venture Exchange under the symbol "VPT", its only operations being those of VentriPoint, Inc.